Research ArticleCancer

Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity

See allHide authors and affiliations

Science Translational Medicine  02 Oct 2019:
Vol. 11, Issue 512, eaax0720
DOI: 10.1126/scitranslmed.aax0720

Tampering with TNFR2

Because tumor necrosis factor receptor 2 (TNFR2) is expressed on effector T cells as well as regulatory T cells, it is unclear whether TNFR2 activation could be exploited for cancer immunotherapy. Tam et al. screened a library of mouse anti-TNFR2 antibodies. One antibody, Y9, showed impressive antitumor activity in multiple implanted models without any toxicity. Efficacy was dependent on the Fc portion of the antibody and most likely mediated by effector T cells. Similar anti-human TNFR2 antibodies could provide costimulation to human cells in vitro and showed efficacy in humanized mouse models. These results suggest that certain TNFR2 antibodies could be developed for use in the clinic.

View Full Text

Stay Connected to Science Translational Medicine